Literature DB >> 10775460

Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase?

S Ren1, M A Correia.   

Abstract

The hepatic cytosolic hemoprotein tryptophan 2,3-dioxygenase (TDO) is the rate-limiting enzyme in tryptophan catabolism and thus plays a key role in regulating the physiological flux of tryptophan into relevant metabolic pathways. The TDO protein is induced by corticosteroids such as dexamethasone (DEX) and is stabilized by its prosthetic heme. In rats, acute chemically induced hepatic heme depletion reduces the functional hepatic TDO levels to 25-30% of basal levels within 1 h, and this decrease persists beyond 28 h of heme depletion at which time only 25-30% of the protein is available for heme incorporation. Since this could stem from impaired de novo synthesis and/or instability of the newly synthesized apoTDO protein in the absence of heme, we examined the specific role of heme in these events in a previously validated rat model of acute hepatic heme depletion triggered by the P450 suicide substrate 3, 5-dicarbethoxy 2,6-dimethyl-4-ethyl-1,4-dihydropyridine. We now show that exogenous heme can reverse the functional impairment of the enzyme observed during hepatic heme depletion and fully restore the impaired DEX-mediated induction of the enzyme to normal. Furthermore, through Northern/slot blot analyses coupled with nuclear run-on studies, we now document that this heme regulation of TDO is exerted primarily at the transcriptional level. Immunoblotting analyses also reveal corresponding changes in the TDO protein, thereby establishing that heme is necessary for DEX-inducible TDO mRNA transcription and subsequent translation. Thus, the TDO gene may contain heme-regulatory elements in addition to the reported glucocorticoid-responsive elements. Together, these findings suggest that clinically, hepatic heme deficiency may enhance the tryptophan flux into synthetic (serotonergic) pathways, not only by depriving prosthetic heme for a functionally competent TDO hemoprotein, its primary catabolic enzyme, but also by impairing the de novo synthesis of this enzyme. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775460     DOI: 10.1006/abbi.2000.1755

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  29 in total

1.  Spectroscopic studies of ligand and substrate binding to human indoleamine 2,3-dioxygenase.

Authors:  Changyuan Lu; Yu Lin; Syun-Ru Yeh
Journal:  Biochemistry       Date:  2010-06-22       Impact factor: 3.162

2.  Ligand migration in human indoleamine-2,3 dioxygenase.

Authors:  Karin Nienhaus; Elena Nickel; Changyuan Lu; Syun-Ru Yeh; G Ulrich Nienhaus
Journal:  IUBMB Life       Date:  2011-03       Impact factor: 3.885

Review 3.  Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal.

Authors:  Maria Almira Correia; Peter R Sinclair; Francesco De Matteis
Journal:  Drug Metab Rev       Date:  2010-09-23       Impact factor: 4.518

4.  Tryptophan catabolism in epithelial ovarian carcinoma.

Authors:  Lynelle P Smith; Benjamin G Bitler; Jennifer K Richer; Jessica L Christenson
Journal:  Trends Cancer Res       Date:  2019

Review 5.  Targeting TDO in cancer immunotherapy.

Authors:  Cheng-Peng Yu; Yun-Lei Song; Zheng-Ming Zhu; Bo Huang; Ying-Qun Xiao; Da-Ya Luo
Journal:  Med Oncol       Date:  2017-03-29       Impact factor: 3.064

Review 6.  Kynurenines in the mammalian brain: when physiology meets pathology.

Authors:  Robert Schwarcz; John P Bruno; Paul J Muchowski; Hui-Qiu Wu
Journal:  Nat Rev Neurosci       Date:  2012-07       Impact factor: 34.870

7.  Genetic polymorphisms affecting susceptibility to mercury neurotoxicity in children: summary findings from the Casa Pia Children's Amalgam clinical trial.

Authors:  James S Woods; Nicholas J Heyer; Joan E Russo; Michael D Martin; Federico M Farin
Journal:  Neurotoxicology       Date:  2014-08-07       Impact factor: 4.294

Review 8.  Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins.

Authors:  George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-10-02       Impact factor: 5.590

Review 9.  IDO and TDO as a potential therapeutic target in different types of depression.

Authors:  Yanjie Qin; Nanxi Wang; Xinlin Zhang; Xuemei Han; Xuejia Zhai; Yongning Lu
Journal:  Metab Brain Dis       Date:  2018-07-16       Impact factor: 3.584

10.  Higher level of heme oxygenase-1 in patients with stroke than TIA.

Authors:  Xin Li; Guangfu Song; Yuling Jin; Hongwei Liu; Changqing Li; Chengwu Han; Shiyan Ren
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.